Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio (Nasdaq: ACET) announced inducement grants to three new employees hired in October 2024. The company granted non-qualified stock options to purchase 59,800 shares at an exercise price of $1.28 per share. The vesting schedule includes 25% after one year, with the remaining 75% vesting monthly over three years. These awards were granted under Adicet's 2022 Inducement Plan, approved by the compensation committee as material inducement for employment in accordance with Nasdaq Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced FDA clearance of an IND amendment to evaluate ADI-001 in idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) as part of its ongoing Phase 1 trial in autoimmune diseases. This expands ADI-001's clinical development program to six autoimmune diseases. Patient enrollment for the IIM and SPS cohort is expected to begin in Q1 2025.
The company plans to report initial clinical data from the Phase 1 study in multiple autoimmune diseases in H1 2025. The ADI-001 Phase 1 program will have four separate arms, enrolling patients with various autoimmune conditions. Enrolled patients will receive a single dose of ADI-001, with primary objectives to evaluate safety and tolerability.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to four new employees hired in September 2024. The awards include non-qualified stock options to purchase a total of 33,600 shares of Adicet's common stock at an exercise price of $1.44 per share.
The vesting schedule for these options is as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan. The compensation committee authorized the awards as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced its upcoming oral presentation at the American Society of Gene & Cell Therapy's (ASGCT) 2024 Advancing Gene and Cell Therapies for Cancer conference. The event is scheduled for October 16-17, 2024, in Philadelphia, PA.
The presentation, titled 'ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Designed for Enhanced Potency and Persistence Against Multiple Oncology Indications', will be delivered by Shon Green, Ph.D. It is part of the 'Novel Targets and Effector Cells' session and is assigned Abstract Number 8.
The presentation is scheduled for October 17, 2024, from 11:15 a.m. to 11:30 a.m. ET. Adicet Bio, a clinical stage biotechnology company, focuses on discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
Adicet Bio (Nasdaq: ACET) has opened enrollment for a Phase 1 clinical trial of ADI-001 in autoimmune diseases. The trial will focus on lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV). Enrollment is currently open for LN patients, with SLE, SSc, and AAV enrollment expected to begin in Q4 2024.
The FDA has granted Fast Track Designation to ADI-001 for relapsed/refractory class III or IV LN treatment. The Phase 1 study consists of three arms, with patients receiving a single dose of ADI-001. Primary objectives include evaluating safety and tolerability, while secondary objectives focus on cellular kinetics, pharmacodynamics, autoantibody titers, and disease activity scores.
Adicet anticipates reporting preliminary clinical data for all indications in the first half of 2025.
Adicet Bio (Nasdaq: ACET) has announced promising clinical biomarker data for ADI-001 from the Phase 1 GLEAN trial, reinforcing its potential as a best-in-class allogeneic cell therapy for autoimmune diseases. Key findings include:
1. Robust tissue trafficking with high levels of ADI-001 in secondary lymphoid tissue
2. Significant chimeric antigen receptor (CAR) T cell activation
3. Complete CD19+ B cell depletion in secondary lymphoid tissue
The data shows superior exposure of ADI-001 in secondary lymphoid tissue compared to published third-party data for alpha-beta CAR T therapies. Adicet is advancing ADI-001 clinical programs in various autoimmune conditions and expects to report initial clinical data in the first half of 2025.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to three new employees hired in August 2024. The awards include non-qualified stock options to purchase a total of 30,600 shares of Adicet's common stock at an exercise price of $1.46 per share.
The vesting schedule for these options is structured as follows: 25% of the shares will vest on the one-year anniversary of each recipient's start date, with the remaining 75% vesting in 36 monthly installments thereafter. Full vesting will occur on the fourth anniversary of the recipient's start date, subject to continued employment.
These awards were granted outside of Adicet's stockholder-approved equity incentive plans, under the company's 2022 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York.
Chen Schor, President and CEO of Adicet Bio, will present on Tuesday, September 10, 2024, at 2:30 p.m. ET. Investors and interested parties can access the live audio webcast through the company's website. An archived replay will be available for 30 days after the presentation.
This conference provides Adicet Bio with an opportunity to showcase its innovative work in cell therapies and potentially attract investor interest. The presentation may offer insights into the company's progress, pipeline, and future plans in the rapidly evolving field of immunotherapy.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company developing allogeneic gamma delta T cell therapies, has appointed Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. Dr. Klickstein brings over two decades of leadership experience in biopharma and biomedical research, currently serving as CEO of Koslapp Therapeutics. His expertise in rheumatology, immunology, and drug development, along with his previous role as Chief Innovation Officer at Adicet, is expected to be valuable as the company advances its autoimmune programs and pipeline of gamma delta CAR T therapies. Dr. Klickstein's background includes co-founding Versanis Bio, leadership positions at Novartis, and academic roles at Brigham and Women's Hospital.
Adicet Bio (Nasdaq: ACET) reported Q2 2024 financial results and business updates. Key highlights include:
1. Expansion of ADI-001 clinical development to include SLE, SSc, and AAV, in addition to lupus nephritis.
2. FDA clearance for ADI-270 IND for relapsed/refractory renal cell carcinoma treatment.
3. Fast Track Designation granted for two product candidates.
4. Strong balance sheet with $224.1 million in cash as of June 30, 2024.
5. Net loss of $29.9 million ($0.33 per share) for Q2 2024.
6. R&D expenses decreased to $25.9 million, while G&A expenses increased slightly to $6.9 million.
7. Cash runway expected into the second half of 2026.
